Featured Publications
Association of renalase with clinical outcomes in hospitalized patients with COVID-19
Safdar B, Wang M, Guo X, Cha C, Chun HJ, Deng Y, Dziura J, El-Khoury JM, Gorelick F, Ko AI, Lee AI, Safirstein R, Simonov M, Zhou B, Desir GV. Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLOS ONE 2022, 17: e0264178. PMID: 35259186, PMCID: PMC8903289, DOI: 10.1371/journal.pone.0264178.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsRenalase levelsIntensive care unit admissionHospitalized COVID-19 patientsMean age 64 yearsCOVID-19Cox proportional hazards modelCare unit admissionPrimary composite outcomeRetrospective cohort studyUse of vasopressorsSevere COVID-19IL-6 levelsAge 64 yearsRisk of deathCOVID-19 subjectsInitial disease severityProportional hazards modelCOVID-19 diseasePlasma renalaseUnit admissionICU admissionCohort studyComposite outcomeCytokine levels
2024
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospital
2023
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, Hudock K, Merck L, Moskowitz A, Apodaca K, Barksdale A, Safdar B, Javaheri A, Sturek J, Schrager H, Iovine N, Tiffany B, Douglas I, Levitt J, Busse L, Ginde A, Brown S, Hager D, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall A, DeClercq J, Lavieri R, Joly M, Orr M, Pulley J, Rice T, Schildcrout J, Semler M, Wang L, Bernard G, Collins S, Becker R, del Zoppo G, Henke P, Holubkov R, Johnson M, Kerr K, Lipman H, Lurie F, Pitt B, Vesely S, Fleg J, Aamodt D, Ayers J, Clark D, Collins J, Cook M, Dixon S, Graves J, Jordan C, Lindsell C, Lopez I, McKeel D, Orozco D, Prato N, Qi A, Qutab M, Stoughton C, Vermillion K, Walsh K, Winchell S, Young T, Franklin R, Wagner E, Walther T, Demitrack M, Johnson J, Walsh R, Bales B, Miller K, Torr D, Barot H, Landreth L, LaRose M, Parks L, Teixeira J, Cardenas S, Ceniceros J, Cunningham A, Kunkel S, Lovato D, Zimmerman B, Nguyen T, Zeger W, Nichols H, Wiedel N, Javaheri A, Stilinovic S, Brokowski C, Lu J, Solberg M, Lee D, Roach K, Tiffany B, Tanner C, Taylor A, Zumbahl J, Syed A, Mason J, Jackson P, Coleman R, Haughey H, Cherabuddi K, James N, Wakeman R, Duncan C, Montero C, Rogers A, Wilson J, Vojnik R, Perez C, Wyles D, Hiller T, Oakes J, Garcia A, Gong M, Mohamed A, Andrea L, Nair R, Nkemdirim W, Lopez B, Boujid S, Torres M, Garcia O, Martinez F, Baduashvili A, Bastman J, Chauhan L, Douin D, Finck L, Licursi A, ten Lohuis C, Zhang S, Bender W, Tovar S, Hayes S, Kurtzman N, Rosseto E, Scaffidi D, Shapiro N, Pak J, Allada G, Briceno G, Peña J, Oh M, Ali H, Beselman S, Eby Y, Klimov V, Hite R, Tanzeem H, Droege C, Winter J, Jackman S, Caudill A, Bayoumi E, Pascual E, Chen P, Mucha S, Thiruchelvam N, Siuba M, Mehkri O, Driver B, Hendrickson A, Kaus O, Ontiveros C, Riehm A, Laudun S, Hudock D, Ensley C, Shaner V, Gentile N, Isenberg D, Reimer H, Cincola P, Harris E, Callahan S, Yamane M, Barrios M, Desai N, Bharara A, Keller M, Majumder P, Dohe C, D’Armiento J, Goldklang M, Wagener G, Fonseca L, Valezquez-Sanchez I, Johnson N, Petersen E, Fuentes M, Newton M, Gundel S, Srinivasan V, Steel T, Robinson B. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA 2023, 329: 1170-1182. PMID: 37039791, PMCID: PMC10091180, DOI: 10.1001/jama.2023.3546.Peer-Reviewed Original ResearchConceptsAngiotensin II type 1 receptorII type 1 receptorRenin-angiotensin systemSevere COVID-19Type 1 receptorCause mortalityRAS agentsRAS modulationPlacebo groupAngiotensin IIIntravenous infusionOdds ratioSafety outcomesCOVID-19Renin-angiotensin system modulationSARS-CoV-2 infectionAcute COVID-19Key secondary outcomesAction of angiotensinKidney replacement therapySupplemental oxygen useCOVID-19 pathophysiologyContinuous intravenous infusionLast followSecondary outcomes